



**Federal Aviation
Administration**

U.S. COVID-19 Vaccinations

**Susan Northrup, MD, MPH
Federal Air Surgeon
28 January 2021**

U.S. Emergency Use Authorization Process

- Companies developing new vaccines can obtain approval without going through the usual Food and Drug Administration protocols
- Once Phase 3 trials are complete, they submit an application
- Two weeks later, the advisory board meets and recommends either to approve or note the EUA. Then the FDA publishes the EUA with the scientific findings from the trials.
- The CDC publishes what groups may receive the vaccine in question



FAA Office of Aerospace Medicine Actions

- Historically, no new treatment or medication has been approved without full FDA approval and one year post approval has elapsed.
- Given the significance of the COVID-19 Pandemic, we took a different path.
 - Reviewed the EUA for side effects and timing
 - Set a grounding period of 48 hours
 - Each vaccine is reviewed separately
 - Policy required full coordination



Federal Aviation
Administration

Other Vaccine Issues

- Ultralow Temperatures for Pfizer
 - CO2 from the Dry Ice
 - Power Requirements
- Transportation of Vaccine
 - Expedited handling
 - Air and Ground
- Vaccination Tiers



Questions



Federal Aviation
Administration